Safety
Up to 6 years of treatment experience in clinical trials(1)

Safety

Safety

Up to 6 years of treatment experience in clinical trials(1)

Up to 6 years of treatment experience in clinical trials1


Tegsedi safety profile

Tegsedi has a manageable safety profile2,3, based on up to 6 years of clinical trial experience1


Safety monitoring

The open label extension of the NEURO-TTR study show that platelet and renal function monitoring continued to be effective in managing the identified risks of thrombocytopenia and acute glomerulonephritis3


Read more
About Tegsedi

About Tegsedi

For your hATTR patients with stage 1 or 2 polyneuropathy, what matters is now

Mode of Action

Mode of Action

Tegsedi targets TTR production in hATTR2,4

Efficacy

Efficacy

Tegsedi significantly delay disease progression vs placebo2

Administration

Administration

Tegsedi is administered as a convenient weekly subcutaneous injection2,4

Tegsedi CONNECT

Tegsedi CONNECT

Empowering independence for people living with hATTR

About hATTR

About hATTR

Hereditary transthyretin amyloidosis is a rapidly progressive and life-shortening disease

References

*In the pivotal Phase-3 NEURO-TTR study, platelet count reductions to below normal (140 x 109/l) were reported for 54% of patients on Tegsedi versus 13% of placebo patients. Three (3%) patients developed platelet counts < 25 x 109/l; one of these patients experienced a fatal intracranial haemorrhage.

  1. Coelho T et al. Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosis. OPR15, 7th Congress of the European Academy of Neurology 2021, 19-22 June 20. 
  2. Tegsedi Summary of Product Characteristics. April 2021.
  3. Brannagan TH, Wang AK, Coelho T, et al. Eur J Neurol. 2020;27(8):1374-1381. doi:10.1111/ene.14285
  4. Benson MD et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22–31 (Suppl Appendix).